Exagen Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
29.4%projected annual EPS growth
Analyst Coverage
7analysts covering
FY Revenue (est.)
$71.7Mnext fiscal year
FY EPS (est.)
-$0.67next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
Monitoring Framework
Key Performance Indicators
AVISE CTD Test Volume Annually137K
AVISE CTD Trailing Twelve-Month Average Selling Price (ASP) Quarterly444.0
Quarterly Revenue Quarterly17.3M
Gross Margin Quarterly59.0%
Watch Items
- Cash Burn and Liquidity RunwayTrigger: Cash balance falling below $15 millionAction: Evaluate additional non-dilutive financing options, renegotiate term loan covenants, or implement further cost-reduction measures.
- AVISE CTD Average Selling Price (ASP) Slower-than-Expected RampTrigger: TTM ASP dropping below $430 per testAction: Accelerate revenue cycle management initiatives and intensify appeals processes with third-party payors.
Research as of 20 Jun 2026